For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.
FDA approved Optune Pax with gemcitabine/nab-paclitaxel, applying alternating electric fields to disrupt mitosis via abdominal arrays, expanding noninvasive, home ...
FDA leaders framed the approval as a step forward for a cancer that has seen few therapeutic breakthroughs, stressing that the pancreatic cancer community deserves better options. The agency also ...
The U.S. Food and Drug Administration has approved a first-of-its-kind, noninvasive device, the Optune Pax, for the treatment of adult patients with locally advanced pancreatic cancer. Approval of ...
February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...
The FDA has cleared a wearable device for adults with locally advanced pancreatic cancer that delivers low-intensity electric fields through adhesive patches placed on the skin. In the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results